SAB Members
Dr. Daniel Holsworth
Dr. Holsworth is CEO of StemNext, LLC, a San Diego, CA-based drug discovery company focused on cosmeceuticals and dermatology therapeutics. He is a drug discovery expert and entrepreneur with over 24 years of research experience, and has served in multiple senior level positions in the biotech industry and Big Pharma, including Amylin Pharmaceuticals and Pfizer Global Research & Development.

Dr. Holsworth has also co-founded three drug discovery companies: P&H Therapeutics, Inc.; ODIN Therapeutics A/S; and StemNext, LLC. His research projects over the years have focused on a variety of therapeutic areas-oncology; cardiovascular, metabolic, and inflammatory diseases; central nervous system (CNS) gene therapy; and most recently, dermatology and have culminated in over half a dozen clinical candidates. Dr. Holsworth earned his doctorate in synthetic organic chemistry from Wayne State University in Detroit, Michigan, and was a Post Doctoral Fellow in Medicinal Chemistry at Parke-Davis Pharmaceuticals in Ann Arbor, Michigan.

Prof. Alexey Moskalev
Alexey Moskalev is professor of Russian Academy of Sciences, Doctor of Biological Sciences, Head of Laboratory of Molecular Radiobiology and Gerontology of Institute of Biology of Komi Research Center, Russian Academy of Sciences. Prof. Moskalev is head of the Department of Ecology of Syktyvkar State University, Head of the Laboratory of Genetics of Agingand Longevity at Moscow Institute of Physics and Technology, lead researcher at Engelhardt Institute of Molecular Biology of Russian Academy of Sciences, main researcher at V.N. Vavilov Institute of General Genetics of Russian Academy of Sciences, lecturer at George Mason University.

Prof. Moskalev is author of more than 70 publications in highly cited journals in the fields of aging genetics, genetics of longevity, radiational genetics. Prof. Moskalev has studied Drosophila genome, including longevity genes and genes of stress-resistance and he has discovered several geroprotectors. He’s a member of editorial boards of the scientific journals: Biogerontology, Frontiers in Genetics of Aging, Aging, Oncotarget, Aging and disease. Author of books on gerontology, anti-aging, such as “Aging and genes”, “120 years of life – just the begining”, “How to defeat your age?”, “Potential geroprotectors”, “Biomarkers of aging”.

News & Publications
Multi-omics approaches to disease
September 16, 2017 – 17:28
High-throughput technologies have revolutionized medical research. The advent of genotyping arrays enabled large-scale genome-wide association studies and methods for examining global transcript levels, which gave rise to the field of “integrative genetics”. Other omics technologies, such as proteomics and metabolomics, are now often incorporated into the everyday methodology of biological researchers. As compared to studies of a single omics type, multi-omics offers the opportunity to understand the flow of information that underlies disease.

Entering the ‘big data’ era in medicinal chemistry
May 15, 2017 – 15:09
Medicinal chemistry is experiencing the advent of the big data era, which biology already entered more than a decade ago, due to the availability of high-throughput genomics technologies. In medicinal chemistry, which is an integral part of drug discovery and traditionally a conservative scientific discipline, big data primarily comprise rapidly increasing numbers of compounds and volumes of associated activity data.
While the practice of medicinal chemistry is just beginning to experience big data phenomena, it is evident that big data will play an increasingly important role going forward. More awareness of big data issues and potential caveats will still need to be raised to positively impact the field.


Contact Us
United Kingdom
  • +44 07471602093
  •  
  • Norway
  • +47 46 22 77 96
  • av@digitalbiopharm.com
  •  
  • United States
  • +7 925 936 11 60
  •  
  •  
  • Russia
  • +7 925 936 11 60
  •  
  •  
  • © Digital BioPharm Ltd 2016.
  •  
  •